-transparent.png){kind=logo}
Disposition of [14C]bumetanide administered intravenously to four healthy volunteers could be described by a triexponential equation. The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively. The largest fraction of dose was eliminated during the second phase; only 17% was eliminated during the last phase. The total plasma clearance averaged 228 ml/min, with renal clearance about one-half of this value. The recovery of unchanged bumetanide in urine over 2 days was 47% of the dose, while the total recovery of radioactivity in urine averaged 82% of dose. In plasma 93% of bumetanide was bound to proteins. Thus bumetanide is rapidly eliminated by both renal and nonrenal mechanisms. The elimination kinetics resembled those described for furosemide.
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
April 1979,
Acta pharmacologica et toxicologica,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
January 1987,
European journal of anaesthesiology,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
March 1993,
European journal of anaesthesiology,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
January 1978,
Anesthesia and analgesia,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
August 1984,
Antimicrobial agents and chemotherapy,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
September 1986,
British journal of clinical pharmacology,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
January 1982,
The Journal of asthma : official journal of the Association for the Care of Asthma,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
December 1995,
Antimicrobial agents and chemotherapy,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
January 1984,
Connective tissue research,
P J Pentikäinen, and
P J Neuvonen, and
M Kekki, and
A Penttilä
January 1982,
Pharmaceutica acta Helvetiae,
